Jeil Pharm - Asset Resilience Ratio
Jeil Pharm (002620) has an Asset Resilience Ratio of 1.84% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Jeil Pharm carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Jeil Pharm's Asset Resilience Ratio has changed over time. See 002620 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Jeil Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002620 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩15.86 Billion | 1.84% |
| Total Liquid Assets | ₩15.86 Billion | 1.84% |
Asset Resilience Insights
- Limited Liquidity: Jeil Pharm maintains only 1.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jeil Pharm Industry Peers by Asset Resilience Ratio
Compare Jeil Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Jeil Pharm (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Jeil Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.80% | ₩16.06 Billion ≈ $10.89 Million |
₩890.43 Billion ≈ $603.43 Million |
-0.71pp |
| 2023-12-31 | 2.51% | ₩22.09 Billion ≈ $14.97 Million |
₩880.00 Billion ≈ $596.36 Million |
+0.36pp |
| 2022-12-31 | 2.15% | ₩18.64 Billion ≈ $12.63 Million |
₩865.68 Billion ≈ $586.66 Million |
+0.06pp |
| 2021-12-31 | 2.09% | ₩18.64 Billion ≈ $12.63 Million |
₩892.42 Billion ≈ $604.78 Million |
+0.99pp |
| 2020-12-31 | 1.10% | ₩9.78 Billion ≈ $6.63 Million |
₩887.40 Billion ≈ $601.37 Million |
+0.05pp |
| 2019-12-31 | 1.05% | ₩8.88 Billion ≈ $6.01 Million |
₩846.47 Billion ≈ $573.64 Million |
+0.65pp |
| 2018-12-31 | 0.40% | ₩3.69 Billion ≈ $2.50 Million |
₩920.09 Billion ≈ $623.53 Million |
-2.05pp |
| 2017-12-31 | 2.45% | ₩4.84 Billion ≈ $3.28 Million |
₩197.59 Billion ≈ $133.90 Million |
+1.81pp |
| 2016-12-31 | 0.64% | ₩3.15 Billion ≈ $2.14 Million |
₩491.98 Billion ≈ $333.41 Million |
-0.06pp |
| 2015-12-31 | 0.70% | ₩3.10 Billion ≈ $2.10 Million |
₩445.17 Billion ≈ $301.68 Million |
-1.86pp |
| 2012-12-31 | 2.56% | ₩9.99 Billion ≈ $6.77 Million |
₩390.77 Billion ≈ $264.82 Million |
-5.11pp |
| 2011-12-31 | 7.67% | ₩29.44 Billion ≈ $19.95 Million |
₩384.13 Billion ≈ $260.32 Million |
-- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more